SYNTARA LIMITED ORDINARY (SNT) Short Interest
SYNTARA LIMITED ORDINARY (ASX:SNT) had 0.24% of shares reported as short positions as of 16 July 2026, representing 4,806,305 shares. SYNTARA LIMITED ORDINARY operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Syntara
Syntara Limited is a clinical-stage drug development company focused on creating novel treatments for blood-related cancers and conditions linked to inflammation and fibrosis. Their expertise lies in amine oxidase inhibitors, targeting extracellular matrix dysfunction to develop medicines for diseases with high unmet needs. The company's lead candidate, amsulostat, is currently in Phase 2 trials for myelofibrosis.
Short position
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4SNT intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Syntara
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss SNT
Start a research thread or post the first pulse update